A retrospective study on the efficacy and safety of Endostar with chemotherapy in EGFR-TKI-resistant NSCLC

	A retrospective study on the efficacy and safety of Endostar with chemotherapy in EGFR-TKI-resistant NSCLC
	Bing Han 1; Yanrong Kang 2; Haiji Wang 4; Jian Wang 1; Rong Shen 5; Shuai Liu 2; Lu Lu 2; Zhigang Sun 2; Nan Zhang 2
发表期刊	BMC PULMONARY MEDICINE
ISSN	1471-2466
	2023
卷号	23 期号:1
英文摘要	Endostar is a strong angiogenesis inhibitor that is effective in treating non-small cell lung cancer (NSCLC), but the effect of Endostar in the treatment of patients with EGFR-TKI-resistant NSCLC remains unclear. We evaluated the clinical efficacy and safety of Endostar in EGFR-mutant NSCLC patients resistant to EGFR inhibition treatment.
语种	英语
文献类型	期刊论文
条目标识符	http://ir.yic.ac.cn/handle/133337/33274
专题	中国科学院烟台海岸带研究所知识产出
作者单位	1.山东大学 2.Central Hospital, Shandong First Medical University 3.中国科学院烟台海岸带研究所 4.青岛大学 5.Shandong Provincial Hospital, Shandong First Medical University
推荐引用方式 GB/T 7714	Bing Han,Yanrong Kang,Haiji Wang,et al. A retrospective study on the efficacy and safety of Endostar with chemotherapy in EGFR-TKI-resistant NSCLC[J]. BMC PULMONARY MEDICINE,2023,23(1).
APA	Bing Han.,Yanrong Kang.,Haiji Wang.,Jian Wang.,Rong Shen.,...&Nan Zhang.(2023).A retrospective study on the efficacy and safety of Endostar with chemotherapy in EGFR-TKI-resistant NSCLC.BMC PULMONARY MEDICINE,23(1).
MLA	Bing Han,et al."A retrospective study on the efficacy and safety of Endostar with chemotherapy in EGFR-TKI-resistant NSCLC".BMC PULMONARY MEDICINE 23.1(2023).